Dec 7, 2018
FDA authorizes ClonoSEQ assay, a next generation sequencing (NGS) test for minimal residual disease
ClonoSEQ assay, a next generation sequencing (NGS)-based test for minimal residual disease (MRD) FDA authorizes first next generation...
118
Dec 17, 2017
FDA Approved for Maintenance: Lenalidomide (Revlimid)
On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid, Celgene Corp.) as maintenance therapy for...
48
Dec 14, 2017
FDA Approved for RRMM: Daratumumab + Pomalidomide & Dexamethasone
HORSHAM, PA, June 16, 2017 – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the...
56
Dec 31, 2016
FDA approves Carfilzomib in combination with Dex or with Lenalidomide and Dex in replased Myeloma
Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the...
124
Dec 7, 2016
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...
178
Dec 19, 2015
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
11/30/2015: Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple...
34
Dec 17, 2015
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib(Velcade) and Dexamethasone Relapsed & Refractory Multiple Myeloma...
90
Dec 14, 2015
FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
July 24, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the...
139
Dec 12, 2015
FDA Approved for RRMM: Daratumumab (Darzalex)
HORSHAM, PA, November 16, 2015 – Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S....
66
Dec 12, 2015
FDA Approved for NDMM: Lenalidomide (Revlimid)
SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug...
32
Dec 10, 2015
FDA Approved for RRMM: Pomalidomide (Pomalyst) + Dexamethasone
April 23, 2015; SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated...
89
Dec 13, 2013
FDA Approved for RRMM: Pomalidomide (Pomalyst)
SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration...
112
Dec 12, 2012
FDA Approved for RRMM: Carfilzomib (PX-171-003-A1) for relapsed refractory multiple myeloma
SOUTH SAN FRANCISCO, Calif., July 25, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Blood, the...
130
Dec 5, 2012
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341) VELCADE SUBCUTANEOUSLY
01/23/2012: FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications CAMBRIDGE, Mass.--(BUSINESS...
114
Dec 9, 2006
FDA Approved for RRMM: Lenalidomide (Revlimid)
SUMMIT, N.J., June 29, 2006 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA)...
46
Dec 10, 2003
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341)
On May 13, 2003, the U.S. Food and Drug Administration (FDA) granted accelerated approval for bortezomib (formerly PS-341), Velcade....
136